Evidence map›Paper›PMID 24954505›Full record

ArticleOncogene2015

The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.

L M Privette Vinnedge, N M Benight, P K Wagh, N A Pease, M A Nashu, J Serrano-Lopez, A K Adams, J A Cancelas, S E Waltz, S I Wells

Abstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. A network map of macrophage-stimulating protein (MSP) signaling.Journal of cell communication and signaling · 2023
    Article
  11. Review
  12. Article
  13. Potential ofMolecular and clinical oncology · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

L M Privette VinnedgeDivision of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
N M BenightDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
P K WaghDepartment of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
N A PeaseDivision of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
M A NashuDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
J Serrano-Lopez1] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA [2] IMIBIC/UCO/University Hospital Reina Sofia, Cordoba, Spain.
A K AdamsDivision of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
J A Cancelas1] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA [2] Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
S E Waltz1] Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA [2] Department of Research, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA.
S I WellsDivision of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

ENVIRONMETAL CARCINOGENESIS AND MUTAGENESIST32ES007250 · NIEHS · UNIVERSITY OF CINCINNATI · PI MILLER, WILLIAM E · 1988 to 2024
$11.9M
ROLE OF ANGPTL4, AN ANGIOGENIC MEDIATOR, IN ARTHRITISP30AR047363 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI FLICK, MATTHEW J. · 2001 to 2015
$9.2M
Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
Ohio Interdisciplinary Women's Health Career TrainingK12HD051953 · NICHD · UNIVERSITY OF CINCINNATI · PI TSEVAT, JOEL · 2005 to 2014
$4.2M
Role and Regulaton of the Human DEK Proto-OncogeneR01CA116316 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI WELLS, SUSANNE I · 2006 to 2016
$2.9M
Training program in hematologic and oncologic diseasesT32HL091805 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI ZHENG, YI · 2008 to 2012
$835k
p130 and Pim-1 as prognostic biomarkers and therapeutic targets in lung cancerF32CA189685 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI WAGH, PURNIMA · 2014 to 2015
$112k
The role of DEK in breast cancer development and therapyF32CA139931 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI PRIVETTE VINNEDGE, LISA M. · 2009 to 2010
$98k
Ron Receptor Tyrosine Kinase Signaling in Breast CancerI01BX000803 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI WALTZ, SUSAN E · 2011 to 2025
–
BLRD VA I01 BX000803NCI NIH HHS F32 CA139931NCI NIH HHS F32CA139931NCI NIH HHS F32 CA189685NCI NIH HHS R01 CA116316NCI NIH HHS R01CA116316NCI NIH HHS T32CA11784NCI NIH HHS T32 CA117846NCI NIH HHS T32CA117846-07NHLBI NIH HHS R01HL875109NHLBI NIH HHS T32 HL091805NHLBI NIH HHS T32HL091805NIAMS NIH HHS AR-47363NIAMS NIH HHS P30 AR047363NICHD NIH HHS K12 HD051953NICHD NIH HHS K12HD051953NIEHS NIH HHS T32 ES007250NIEHS NIH HHS T32ES007250
6 · The paper itself

Abstract

Disease progression and recurrence are major barriers to survival for breast cancer patients. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron (Recepteur d'Origine Nantaise) and DEK, cooperate to promote advanced disease through multipronged effects on β-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron overexpression in human disease stimulates β-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including β-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion. Mechanistically, Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/paracrine canonical β-catenin signaling loop. Finally, we show that Dek overexpression promotes tumorigenic phenotypes in immortalized human mammary epithelial MCF10A cells and, in the context of Ron receptor activation, correlates with disease recurrence and metastasis in patients. Overall, our studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/β-catenin signaling.

Indexed as

Wnt Signaling PathwayAnimalsBreast NeoplasmsCell Line, TumorCell ProliferationChromosomal Proteins, Non-HistoneDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasms, ExperimentalOncogene ProteinsPoly-ADP-Ribose Binding ProteinsReceptor Protein-Tyrosine KinasesChromosomal Proteins, Non-HistoneDEK protein, humanDEK protein, mouseDNA-Binding ProteinsOncogene ProteinsPoly-ADP-Ribose Binding ProteinsReceptor Protein-Tyrosine KinasesRON protein

Identifiers

PMID24954505
PMCPMC4275425
OpenAlexW2015057249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.